<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930641</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258A2308</org_study_id>
    <nct_id>NCT03930641</nct_id>
  </id_info>
  <brief_title>Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter, Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration to Evaluate the Safety of Brolucizumab 6 mg in Prefilled Syringe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label study that is designed to evaluate the safety of
      brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular
      degeneration and to support collection of observations of the prefilled syringe use for
      intravitreal injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>study with a single arm: brolucizumab 6 mg PFS</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of brolucizumab 6 mg delivered in prefilled syringe in patients with neovascular age related macular degeneration</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>The safety is defined as the incidence of ocular and non-ocular adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Neovascular Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>RTH258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>brolucizumab 6 mg in a prefilled syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTH258</intervention_name>
    <description>6 mg in prefilled syringe</description>
    <arm_group_label>RTH258</arm_group_label>
    <other_name>brolucizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed.

          2. Study eye is diagnosed with neovascular age related macular degeneration and would
             need an intravitreal injection.

          3. Subjects &gt;= 50 years of age.

        Exclusion Criteria:

          1. Active infection or inflammation in the eyes.

          2. Uncontrolled glaucoma.

          3. History of a medical, ocular or non-ocular conditions, resulting in that the study
             medication cannot be safely administered.

          4. Treatment with anti-VEGF intravitreal injection in the study eye within one month
             prior to enrollment.

          5. The use of intraocular corticosteroids in the study eye within the last three months
             prior to enrollment.

          6. Recent intraocular surgery, prior long-acting therapeutic agent, or ocular drug
             release device implantation.

          7. Uncontrolled hypertension.

        Other protocol defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brolucizumab 6 mg prefilled syringe PFS</keyword>
  <keyword>open label study</keyword>
  <keyword>neovascular age related macular degeneration intravitreal injection IVT</keyword>
  <keyword>observation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of the patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>June 23, 2020</submitted>
    <returned>July 9, 2020</returned>
    <submitted>July 16, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

